Company News: Anergis Appoints Klaus Schollmeier as New Chairman of the Board of Directors

Senior Pharma and Biotech Executive joins Anergis´ Board of Directors as New Chairman

Anergis SA, a Swiss clinical-stage biopharmaceutical company developing proprietary products for ultra-fast allergy immunotherapy, today announced the appointment of Dr. Klaus Schollmeier as Chairman of its Board of Directors.

Mr. Schollmeier has been a senior executive and advisor to the pharmaceutical and biotech industries for more than 30 years and has senior leadership experience in R&D, Marketing as well as General Management.

“We are delighted and honored to welcome Klaus Schollmeier to Anergis,” said Vincent Charlon, CEO of Anergis. “We are also very grateful to Jacques-François Martin for his support and key contributions during his tenure as Chairman of our Board of Directors from 2012 to 2016.”

“Anergis has successfully collected promising Phase II clinical data on its lead product candidate and I look very much forward to contributing to the company’s lead Phase II program and full product pipeline derived from the long contiguous overlapping peptide technology platform,” said Dr. Klaus Schollmeier, the newly elected Chairman.

“It has been a great pleasure to work closely and efficiently with the board and with Vincent Charlon,” added Jacques-François Martin. “I wish Klaus Schollmeier and the Anergis Team all the best in achieving future milestones for the company.”

From 2013 to 2015 Mr. Schollmeier was the CEO of SuppreMol, Munich, Germany, when the company was sold to Baxalta. From 2004 to 2011 he served as CEO of Santhera, Basel, Switzerland, and as Chairman of the Board of Santhera until 2013. Mr. Schollmeier joined Graffinity Pharmaceuticals AG, Heidelberg, Germany, as CEO in 2003, and in 2004 merged the company with MyoContract AG, Basel, Switzerland, to form Santhera. Prior to joining the biotechnology industry in 2003, he was a managing director with the healthcare/biotechnology group at ING-BHF Bank for ING Group Europe. Before then, he spent 16 years in the pharmaceutical industry at BASF, Knoll and Abbott. His scientific roles included Head of Oncology/Immunology Research at BASF’s central laboratories in Ludwigshafen, Germany, and, from 1989 to 1993, Senior Director of Biotechnology at BASF Bioresearch Corporation in Cambridge, Massachusetts, USA. He was also a general manager at BASF Pharma Netherlands from 1996 to 1998, and subsequently Vice President and General Manager for Western Europe. Throughout his career he conceived and executed multiple strategic licensing deals and mergers and acquisitions between pharma companies and pharmaceutical and biotech companies. Mr. Schollmeier has a PhD in Biology from the University of Dusseldorf, Germany. In 1991, he became an adjunct research associate professor at Boston University Medical School, Massachusetts, USA.